KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)
Clinical trial NCT04165096 · COMPLETED
Trial details
- NCT number
- NCT04165096
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-21
- Primary completion
- 2025-04-30
- Enrollment
- 128
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.